MAIA Biotechnology (NYSEAMERICAN:MAIA) Releases Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Key Points

• MAIA reported adjusted EPS of ($0.08), beating the consensus estimate of ($0.13) by $0.05.
• Shares opened at $1.46 with a 50-day/200-day moving average of $1.94/$1.58, a 12-month range of $0.87–$3.19, and a market capitalization of $56.44 million.
• MAIA is a clinical-stage biopharmaceutical company developing site-specific antibody–radioisotope conjugates for PET imaging and targeted radiotherapeutics, with several preclinical candidates showing favorable targeting and pharmacokinetics.

MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.05, FiscalAI reports.

MAIA Biotechnology Price Performance

Shares of MAIA stock opened at $1.46 on Monday. The firm's 50-day moving average is $1.94 and its two-hundred day moving average is $1.58. MAIA Biotechnology has a 12 month low of $0.87 and a 12 month high of $3.19. The company has a market capitalization of $56.44 million, a PE ratio of -2.00 and a beta of -0.04.

Institutional Trading of MAIA Biotechnology

Several hedge funds have recently made changes to their positions in MAIA. Marshall Wace LLP purchased a new stake in shares of MAIA Biotechnology during the 2nd quarter valued at approximately $29,000. Jane Street Group LLC purchased a new position in MAIA Biotechnology in the second quarter worth approximately $52,000. Finally, Geode Capital Management LLC increased its stake in MAIA Biotechnology by 3.6% during the second quarter. Geode Capital Management LLC now owns 222,183 shares of the company's stock worth $400,000 after acquiring an additional 7,746 shares during the last quarter. Hedge funds and other institutional investors own 5.65% of the company's stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.